Programma Scientifico

FEBRUARY 25th 2021

15.30-15.45 Welcome and introduction
A. Antinori, A. d’Arminio Monforte
Data updates from the ICONA Cohort

SESSION 1: HIV AND SARS-COV-2

Moderators: M. Galli, G. Ippolito

15.45-16.00 Lecture Are PLWH at higher risk of worse COVID-19 prognosis compared with HIV neg? A. Antinori
16.00-16.15 Impact of lockdown on HIV care in Italy C. Pinnetti
16.15-16.30 Study proposals on HIV SARS-CoV-2 coinfection from the ICONA Cohort F. Ceccherini-Silberstein, G. Marchetti
16.30-16.45 Discussion conducted by Moderators

SESSION 2: IMMUNO VIROLOGICAL DATA

Moderators: M. Andreoni, A. Gori

16.45-17.00 Lecture HIV virological issues in 2020 C.F. Perno
17.00-17.10 Impact of multi-drug resistance on mortality: a multi-cohort Italian study A. Cozzi-Lepri
17.10-17.20 Stable total HIV-DNA after 1 year on switch to TAF-based regimens in real world data C. Alteri
17.20-17.35 Discussion conducted by Moderators

SESSION 3: QUALITY OF LIFE IN PLWH

Moderators: R. Cauda, R. Iardino, F. von Schloesser

17.35-17.50 Lecture Patient reported outcomes to value innovation in HIV treatment O. Ciani
Round table on significance of PROs in HIV management
17.50-18.05 The role of innovative therapies A. Castagna
18.05-18.20 PROs measurements: implications and consequences F. Maggiolo
18.20-18.35 Patients perspective on PROs M. Errico
18.35-18.50 ICONA e-QoL Project A. Cingolani
18.50-19.05 Discussion conducted by Moderators
19.05-19.15 Take-home messages from first working sessions A. Antinori, A. d’Arminio Monforte

FEBRUARY 26th 2021

15.00-15.30 Presentation of the ICONA App

SESSION 4: CLINICAL ISSUES

Moderators: F. Castelli, M. Puoti

15.30-15.45 Lecture Weight gain: the state of art G. Guaraldi
15.45-15.55 Causes and incidence of hospitalization in patients enrolled in the ICONA Cohort S. Nozza
15.55-16.05 Risk of multiple primary neoplasms and impact on survival of person living with HIV (PLWH) V. Mazzotta
16.05-16.15 Risk of weight gain (WG) according to type of switching strategy in a large Cohort of HIV-infected individuals with stable suppressed HIV-RNA S. Cicalini
16.15-16.30 Discussion conducted by Moderators

SESSION 5: ANTIRETROVIRAL THERAPY

Moderators: G. Di Perri, C. Mussini

16.30-16.40 Adults with multidrug resistant HIV-1 infection for whom it is not possible to construct a suppressive ARV regimen due to resistance, intolerance or safety considerations in the Italian ICONA Cohort S. Lo Caputo
16.40-16.50 Reasons for choosing a 2DR or a TAF-based 3DR as ART switch strategy in second line therapies for virologically suppressed PLWH in Italy A. Vergori
16.50-17.05 Discussion conducted by Moderators

SESSION 6: EPIDEMIOLOGY and SOCIAL ISSUES

Moderators: A. Lazzarin, G. Rezza, A. Perziano

17.05-17.20 Lecture Are PLWH at higher risk of SARS-CoV-2 infection compared with HIV neg? E. Girardi
17.20-17.30 Post-migration HIV infection in the foreign-born population enrolled in the ICONA Cohort A. Saracino
17.30-17.40 U=U status in people living with HIV after switching to dual antiretroviral therapy: results from the ICONA Cohort G. Madeddu
17.40-17.50 Awareness and perception of accuracy of the Undetectable=Untransmittable (U=U) message in people living with HIV/AIDS (PLWHA) in Italy and correlation with the level of confidence in reference physicians A. Cingolani
17.50-18.05 Discussion conducted by Moderators
18.05-18.15 Final considerations A. Antinori, A. d’Arminio Monforte
×